USF-LVHN SELECT
Effectiveness and Safety of Outpatient Monoclonal Antibody Use for the Treatment of COVID-19 in Children and Adolescents: Single Center Study.
Publication/Presentation Date
10-1-2025
Abstract
OBJECTIVE: Monoclonal antibody therapy has been used to treat COVID-19, with paucity of literature about its use in children. This retrospective study sought to evaluate the effectiveness of preventing hospitalization and safety of monoclonal antibody (mAb) treatment (bamlanivimab-etesevimab and casirivimab-imdevimab) for COVID-19 in patients ≤18 years of age.
METHODS: Between January 1 and December 31, 2021, patients were selected for mAb therapy, based on the referring provider's clinical assessment of high risk for progression to severe COVID-19. The choice of mAb was determined by drug availability, compounding feasibility, and documented
RESULTS: Of 141 patients who received mAbs in 2021, only 3 experienced ongoing COVID-19 symptoms. Only 1 patient necessitated escalated care owing to persistent COVID-19 symptoms post infusion. There were no infusion-related side effects or hospitalizations in the 90 days post infusion.
CONCLUSION: Monoclonal antibodies appear to be safe and effective in preventing hospitalizations in COVID-19-positive children.
Volume
30
Issue
5
First Page
655
Last Page
659
ISSN
1551-6776
Published In/Presented At
Cheng, J., Heideman, E., Espinosa, C., Zeitler, K., Piccicacco, N., & Gaviria-Agudelo, C. (2025). Effectiveness and Safety of Outpatient Monoclonal Antibody Use for the Treatment of COVID-19 in Children and Adolescents: Single Center Study. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 30(5), 655–659. https://doi.org/10.5863/JPPT-24-00095
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
41112342
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article